RVXCF (Resverlogix) Cyclically Adjusted PB Ratio: (As of Jul. 18, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Resverlogix Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Resverlogix  (OTCPK:RVXCF) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Resverlogix Cyclically Adjusted PB Ratio Related Terms


Resverlogix Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Resverlogix's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Resverlogix Cyclically Adjusted PB Ratio Chart

Resverlogix Annual Data
Trend Apr16 Apr17 Apr18 Apr19 Apr20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Resverlogix Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

RVXCF vs VRTX, REGN, ALNY: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Resverlogix's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Resverlogix Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Resverlogix's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Resverlogix's Cyclically Adjusted PB Ratio falls into.



Resverlogix Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Resverlogix's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 is calculated as:

For example, Resverlogix's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book=Book Value per Share/CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.285/132.2623*132.2623
=-0.285

Current CPI (Mar. 2026) = 132.2623.

Resverlogix Quarterly Data

Book Value per Share CPI Adj_Book
201604 -0.536 101.370 -0.699
201607 -0.595 101.844 -0.773
201610 -0.737 102.002 -0.956
201701 -0.858 102.318 -1.109
201704 -0.961 103.029 -1.234
201707 -1.000 103.029 -1.284
201710 -1.037 103.424 -1.326
201801 -0.448 104.056 -0.569
201804 -0.472 105.320 -0.593
201807 -0.749 106.110 -0.934
201810 -0.826 105.952 -1.031
201901 -0.801 105.557 -1.004
201904 -1.037 107.453 -1.276
201907 -0.951 108.243 -1.162
201910 -0.392 107.927 -0.480
202001 -0.355 108.085 -0.434
202004 -0.303 107.216 -0.374
202007 -0.310 108.401 -0.378
202010 -0.226 108.638 -0.275
202103 -0.166 110.298 -0.199
202106 -0.160 111.720 -0.189
202109 -0.179 112.905 -0.210
202112 -0.246 113.774 -0.286
202203 -0.244 117.646 -0.274
202206 -0.239 120.806 -0.262
202209 -0.228 120.648 -0.250
202212 -0.223 120.964 -0.244
202303 -0.239 122.702 -0.258
202306 -0.248 124.203 -0.264
202309 -0.263 125.230 -0.278
202312 -0.273 125.072 -0.289
202403 -0.266 126.258 -0.279
202406 -0.280 127.522 -0.290
202409 -0.297 127.285 -0.309
202412 -0.290 127.364 -0.301
202503 -0.306 129.181 -0.313
202506 -0.310 129.892 -0.316
202509 -0.310 130.287 -0.315
202512 -0.309 130.366 -0.313
202603 -0.285 132.262 -0.285

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Resverlogix Business Description

Other Exchanges RVX:Canada
Address 4820 Richard Road SW, Suite 300, Calgary, AB, CAN, T3E 6L1
Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with chronic disease, including cardiovascular disease (CVD) and associated comorbidities, and COVID-19.